Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review

Kumar, S.; Pallin, Michael; Soldatos, Georgia; Teede, Helena

doi:10.1016/j.jcte.2022.100305

Cited by 4 publications

(8 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the conflicting results between the aforementioned studies, they provide the most thorough evidence on the associations between CGM measures, OGTT, and CF outcomes [ 40 ]. Further studies are needed to test these CGM screening thresholds in larger validation samples.…”

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

“…In 2022, a systematic review by Kumar et al assessed the relative risk of an arbitrary CGM diagnosis of diabetes compared to an OGTT diagnosis [ 40 ]. Studies reporting concurrent CGM measures and OGTT results were included.…”

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

“…CGM hyperglycemia in those with NGT or AGT was considered an arbitrary CGM-CFRD diagnosis. The authors reported that the relative risk of an arbitrary CGM-CFRD diagnosis compared to OGTT-defined CFRD was 2.92, concluding that a single CGM reading >11.1 mmol/L is not a suitable cut-off for CFRD [ 40 ].…”

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

“…Patients with CF have various epidemiological, genetic, therapeutic, and clinical features that may impact glycemia and lead to bidirectional changes in glycemic status, which have been observed using both OGTT and CGM [ 12 , 35 , 40 ]. In addition, β-cell responsiveness is a dynamic process [ 45 ], which makes it difficult to define dysglycemia, irrespective of the screening test used.…”

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

“…Prolonged CGM duration or multiple CGM acquisitions could also alleviate some of the issues of non-standardization. Although most studies have used CGM during periods of stable disease, the earliest signs of β-cell dysfunction might be evident during acute illnesses, such as pulmonary exacerbations [ 40 ].…”

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

See 4 more Smart Citations

The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis

Kirigin Biloš,

Altabas,

Vukić Dugac

et al. 2024

Medicina

View full text Add to dashboard Cite

Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in patients with cystic fibrosis (CF). CFRD has been correlated with important clinical outcomes, including poor nutrition, reduced pulmonary function, and earlier mortality. However, clinical decline due to abnormalities of blood glucose (dysglycemia) begins early in CF, before the diagnosis of CFRD by the gold-standard oral glucose tolerance test (OGTT). Continuous glucose monitoring (CGM) has been validated in patients with CF and has been recognized as a valuable tool in detecting early glucose abnormalities in patients with CF. Several CGM parameters have been used to predict CFRD in some but not all studies, and there is no consensus regarding CGM use for diagnostic purposes. Thus, it remains a complementary test to OGTT in CFRD diagnosis. The aim of this review is to provide an update on the pathophysiological mechanisms of CFRD, recent advances in the use of CGM for CFRD screening, and the association between CGM measures and CF-related clinical outcomes.

show abstract

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

Section: Continuous Glucose Monitoring In Cfrd Screeningmentioning

confidence: 99%

See 3 more Smart Citations

The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis

Kirigin Biloš,

Altabas,

Vukić Dugac

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

Advances in diabetes technology to improve the lives of people with cystic fibrosis

Scully,

Marks,

Putman

2024

Diabetologia

View full text Add to dashboard Cite

Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease

et al. 2023

View full text Add to dashboard Cite

Application of continuous glucose monitoring (CGM) has moved diabetes care from a reactive to a proactive process, in which a person with diabetes can prevent episodes of hypoglycemia or hyperglycemia, rather than taking action only once low and high glucose are detected. Consequently, CGM devices are now seen as the standard of care for people with type 1 diabetes mellitus (T1DM). Evidence now supports the use of CGM in people with type 2 diabetes mellitus (T2DM) on any treatment regimen, not just for those on insulin therapy. Expanding the application of CGM to include all people with T1DM or T2DM can support effective intensification of therapies to reduce glucose exposure and lower the risk of complications and hospital admissions, which are associated with high healthcare costs. All of this can be achieved while minimizing the risk of hypoglycemia and improving quality of life for people with diabetes. Wider application of CGM can also bring considerable benefits for women with diabetes during pregnancy and their children, as well as providing support for acute care of hospital inpatients who experience the adverse effects of hyperglycemia following admission and surgical procedures, as a consequence of treatment-related insulin resistance or reduced insulin secretion. By tailoring the application of CGM for daily or intermittent use, depending on the patient profile and their needs, one can ensure the cost-effectiveness of CGM in each setting. In this article we discuss the evidence-based benefits of expanding the use of CGM technology to include all people with diabetes, along with a diverse population of people with non-diabetic glycemic dysregulation. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-023-01431-3.

show abstract

Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review

Cited by 4 publications

References 88 publications

The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis

The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis

Advances in diabetes technology to improve the lives of people with cystic fibrosis

Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease

Contact Info

Product

Resources

About